Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis
Corresponding Author
Jeremie Zerbit
Pharmacy Department, Hospital at Home, University Hospitals of Paris (AP-HP), Paris, France
Correspondence
Jeremie Zerbit, Pharmacy Department, Hospital at Home, University Hospitals of Paris (AP-HP), Paris, France.
Email: [email protected]
Search for more papers by this authorMarie Kroemer
Pharmacy Department, University Hospital of Besançon, Besançon, France
Search for more papers by this authorBasile Fuchs
Medical Information, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorMarion Detroit
Pharmacy Department, University Hospital of Besançon, Besançon, France
Search for more papers by this authorJustine Decroocq
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorMarguerite Vignon
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorLise Willems
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorBénédicte Deau-Fischer
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorPatricia Franchi
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorPaul Deschamps
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorAdrien Contejean
Clinical Hematology, Annecy Genevois Hospital, Annecy, France
Search for more papers by this authorEric Grignano
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorGuillemette Fouquet
Hematology Department, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
Search for more papers by this authorRudy Birsen
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorJohanna Mondesir
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorMathieu Rocquet
Hematology Department, Necker Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorJean-François Huon
INSERM, UMR 1246-SPHERE, MethodS in Patients-Centered Outcomes and HEalth ResEarch, Nantes, France
Clinical Pharmacy Unit, Nantes University Hospital, Nantes, France
Search for more papers by this authorRui Batista
Clinical Pharmacy, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorJeanne Marty-Reboul
Medical Information, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorDidier Bouscary
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorCorresponding Author
Jeremie Zerbit
Pharmacy Department, Hospital at Home, University Hospitals of Paris (AP-HP), Paris, France
Correspondence
Jeremie Zerbit, Pharmacy Department, Hospital at Home, University Hospitals of Paris (AP-HP), Paris, France.
Email: [email protected]
Search for more papers by this authorMarie Kroemer
Pharmacy Department, University Hospital of Besançon, Besançon, France
Search for more papers by this authorBasile Fuchs
Medical Information, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorMarion Detroit
Pharmacy Department, University Hospital of Besançon, Besançon, France
Search for more papers by this authorJustine Decroocq
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorMarguerite Vignon
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorLise Willems
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorBénédicte Deau-Fischer
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorPatricia Franchi
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorPaul Deschamps
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorAdrien Contejean
Clinical Hematology, Annecy Genevois Hospital, Annecy, France
Search for more papers by this authorEric Grignano
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorGuillemette Fouquet
Hematology Department, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
Search for more papers by this authorRudy Birsen
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorJohanna Mondesir
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorMathieu Rocquet
Hematology Department, Necker Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorJean-François Huon
INSERM, UMR 1246-SPHERE, MethodS in Patients-Centered Outcomes and HEalth ResEarch, Nantes, France
Clinical Pharmacy Unit, Nantes University Hospital, Nantes, France
Search for more papers by this authorRui Batista
Clinical Pharmacy, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorJeanne Marty-Reboul
Medical Information, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Search for more papers by this authorDidier Bouscary
Clinical Hematology, Cochin Hospital, University Hospitals of Paris (AP-HP), Paris, France
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France
Search for more papers by this authorFunding information: No funding.
Abstract
Objective
The clinical benefit of pharmaceutical cares in improving the quality-of-care outcomes is well demonstrated. Clinical pharmacy services are not systematically deployed in cancer units in the absence of economic data. The aim of this prospective, observational 1-year study was to evaluate the clinical, economic and organisational impacts of pharmaceutical care into a multidisciplinary day hospital for patients treated with oral cancer drugs.
Methods
All pharmacists' interventions (PI) were documented and their impact and the probability of adverse drug events were assessed using the clinical, economic and organisational tool.
Results
Among 360 admissions, an average of 1.81 PI per admission was accepted. Among 452 PI leading to a clinical benefit on the patient, 16.9% had a major impact, and 1.9% had an impact on survival. The large majority of PIs (87%) increased the quality-of-care organisation. The budget impact model showed a total cost savings and cost avoidance of €539,047 per year and a cost–benefit ratio of 7.07:1. The direct cost–benefit was €201,741, and the cost avoidance was €337,306.
Conclusion
Multidisciplinary care and pharmaceutical care are key elements to improve cancer patients' outcomes and avoid evitable healthcare costs.
CONFLICT OF INTEREST
No conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
The datasets analysed during the current study are available from the corresponding author on reasonable request.
REFERENCES
- Allenet, B., Bedouch, P., Rose, F.-X., Escofier, L., Roubille, R., Charpiat, B., Juste, M., & Conort, O. (2006). Validation of an instrument for the documentation of clinical pharmacists' interventions. Pharmacy World & Science, 28, 181–188. https://doi.org/10.1007/s11096-006-9027-5
- Bates, D. W., Spell, N., Cullen, D. J., Burdick, E., Laird, N., Petersen, L. A., Small, S. D., Sweitzer, B. J., & Leape, L. L. (1997). The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA, 277, 307–311. https://doi.org/10.1001/jama.1997.03540280045032
- Baudouin, A., Herledan, C., Poletto, N., Guillemin, M.-D., Maison, O., Garreau, R., Chillotti, L., Parat, S., Ranchon, F., & Rioufol, C. (2021). Economic impact of clinical pharmaceutical activities in hospital wards: A systematic review. Research in Social & Administrative Pharmacy, 17, 497–505. https://doi.org/10.1016/j.sapharm.2020.07.016
- Bedouch, P., Sylvoz, N., Charpiat, B., Juste, M., Roubille, R., Rose, F.-X., Bosson, J.-L., Conort, O., Allenet, B., & French Society of Clinical Pharmacy's Act-IP© Group. (2015). Trends in pharmacists' medication order review in French hospitals from 2006 to 2009: Analysis of pharmacists' interventions from the Act-IP© website observatory. Journal of Clinical Pharmacy and Therapeutics, 40, 32–40. https://doi.org/10.1111/jcpt.12214
- Chan, A., Soh, D., Ko, Y., Huang, Y.-C., & Chiang, J. (2014). Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients. Supportive Care in Cancer, 22, 1875–1881. https://doi.org/10.1007/s00520-014-2160-0
- Conort, O., Bedouch, P., Juste, M., Augereau, L., Charpiat, B., Roubille, R., & Allenet, B. (2004). Validation of a coding tool for clinical pharmacy interventions. Journal de Pharmacie Clinique, 23, 141–147.
- Escudero-Vilaplana, V., Ribed, A., Romero-Jimenez, R. M., Herranz-Alonso, A., & Sanjurjo-Saez, M. (2017). Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents. European Journal of Cancer Care, 26, e12463. https://doi.org/10.1111/ecc.12463
- Gallagher, J., McCarthy, S., & Byrne, S. (2014). Economic evaluations of clinical pharmacist interventions on hospital inpatients: A systematic review of recent literature. International Journal of Clinical Pharmacy, 36, 1101–1114. https://doi.org/10.1007/s11096-014-0008-9
- Girre, V., Arkoub, H., Puts, M. T. E., Vantelon, C., Blanchard, F., Droz, J. P., & Mignot, L. (2011). Potential drug interactions in elderly cancer patients. Critical Reviews in Oncology/Hematology, 78, 220–226. https://doi.org/10.1016/j.critrevonc.2010.05.004
- Hoonhout, L. H. F., de Bruijne, M. C., Wagner, C., Asscheman, H., van der Wal, G., & van Tulder, M. W. (2010). Nature, occurrence and consequences of medication-related adverse events during hospitalization. Drug Safety, 33, 853–864. https://doi.org/10.2165/11536800-000000000-00000
- Kopp, B. J., Mrsan, M., Erstad, B. L., & Duby, J. J. (2007). Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. American Journal of Health-System Pharmacy, 64, 2483–2487. https://doi.org/10.2146/ajhp060674
- Laurent, V., Saillard, J., Thierry, M., Lepelletier, A., Fronteau, C., & Huon, J.-F. (2021). Anticancer agents and phytotherapy: Interactions that are often unrecognized. Journal of Oncology Pharmacy Practice, 27, 322–328. https://doi.org/10.1177/1078155220920363
- Maggiore, R. J., Dale, W., Gross, C. P., Feng, T., Tew, W. P., Mohile, S. G., Owusu, C., Klepin, H. D., Lichtman, S. M., Gajra, A., Ramani, R., Katheria, V., Zavala, L., Hurria, A., & Cancer and Aging Research Group. (2014). Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: Effect on chemotherapy-related toxicity and hospitalization during treatment. Journal of the American Geriatrics Society, 62, 1505–1512. https://doi.org/10.1111/jgs.12942
- Molassiotis, A., Brearley, S., Saunders, M., Craven, O., Wardley, A., Farrell, C., Swindell, R., Todd, C., & Luker, K. (2009). Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: A randomized, controlled trial. Journal of Clinical Oncology, 27, 6191–6198. https://doi.org/10.1200/JCO.2008.20.6755
- Nazer, L. H., & Tuffaha, H. (2017). Health care and pharmacy practice in Jordan. The Canadian Journal of Hospital Pharmacy, 70, 150–155. https://doi.org/10.4212/cjhp.v70i2.1649
- NCC MERP. (2014). National coordination council for medication error reporting and prevention index of medication errors [text]. Retrieved from https://www.nccmerp.org/types-medication-errors
- Nerich, V., Limat, S., Demarchi, M., Borg, C., Rohrlich, P. S., Deconinck, E., Westeel, V., Villanueva, C., Woronoff-Lemsi, M. C., & Pivot, X. (2010). Computerized physician order entry of injectable antineoplastic drugs: An epidemiologic study of prescribing medication errors. International Journal of Medical Informatics, 79, 699–706. https://doi.org/10.1016/j.ijmedinf.2010.07.003
- Nesbit, T. W., Shermock, K. M., Bobek, M. B., Capozzi, D. L., Flores, P. A., Leonard, M. C., Long, J. K., Militello, M. A., White, D. A., Barone, L. D., Goldman, M. P., & Kvancz, D. A. (2001). Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. American Journal of Health-System Pharmacy, 58, 784–790. https://doi.org/10.1093/ajhp/58.9.784
- Neuss, M. N., Polovich, M., McNiff, K., Esper, P., Gilmore, T. R., LeFebvre, K. B., Schulmeister, L., & Jacobson, J. O. (2013). 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. Journal of Oncology Practice, 9, 5s–13s. https://doi.org/10.1200/JOP.2013.000874
- Neville, H. L., Chevalier, B., Daley, C., Nodwell, L., Harding, C., Hiltz, A., MacDonald, T., Skedgel, C., MacKinnon, N. J., & Slayter, K. (2014). Clinical benefits and economic impact of post-surgical care provided by pharmacists in a Canadian hospital. The International Journal of Pharmacy Practice, 22, 216–222. https://doi.org/10.1111/ijpp.12058
- Nightingale, G., Hajjar, E., Swartz, K., Andrel-Sendecki, J., & Chapman, A. (2015). Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. Journal of Clinical Oncology, 33, 1453–1459. https://doi.org/10.1200/JCO.2014.58.7550
- Pharmaceutical Care Network Europe. (2020). Classification for drug related problems V9.1 [text]. Retrieved from https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf
- Prithviraj, G. K., Koroukian, S., Margevicius, S., Berger, N. A., Bagai, R., & Owusu, C. (2012). Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. Journal of Geriatric Oncology, 3, 228–237. https://doi.org/10.1016/j.jgo.2012.02.005
- Renaudin, P., Coste, A., Audurier, Y., Berbis, J., Canovas, F., Jalabert, A., Castet-Nicolas, A., Mercier, G., Villiet, M., Dagneaux, L., & Breuker, C. (2021). Clinical, economic, and organizational impact of the clinical pharmacist in an orthopedic and trauma surgery department. Journal of Patient Safety, 17, e1507–e1513. https://doi.org/10.1097/PTS.0000000000000539
- Research, studies, evaluation and statistics department of French Government. (2010). Serious adverse events in healthcare facilities: Frequency, avoidability and acceptability [text]. Retrieved from https://drees.solidarites-sante.gouv.fr/sites/default/files/2020-10/dss17.pdf
- Ribed, A., Romero-Jiménez, R. M., Escudero-Vilaplana, V., Iglesias-Peinado, I., Herranz-Alonso, A., Codina, C., & Sanjurjo-Sáez, M. (2016). Pharmaceutical care program for onco-hematologic outpatients: Safety, efficiency and patient satisfaction. International Journal of Clinical Pharmacy, 38, 280–288. https://doi.org/10.1007/s11096-015-0235-8
- Riechelmann, R. P., Tannock, I. F., Wang, L., Saad, E. D., Taback, N. A., & Krzyzanowska, M. K. (2007). Potential drug interactions and duplicate prescriptions among cancer patients. Journal of the National Cancer Institute, 99, 592–600. https://doi.org/10.1093/jnci/djk130
- Segal, E. M., Bates, J., Fleszar, S. L., Holle, L. M., Kennerly-Shah, J., Rockey, M., & Jeffers, K. D. (2019). Demonstrating the value of the oncology pharmacist within the healthcare team. Journal of Oncology Pharmacy Practice, 25, 1945–1967. https://doi.org/10.1177/1078155219859424
- Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., & Thiele, J. (2017). WHO classification of tumours of haematopoietic and lymphoid tissues [text]. Retrieved from https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017
- Van den Bemt, P. M., Egberts, T. C., de Jong-van den Berg, L. T., & Brouwers, J. R. (2000). Drug-related problems in hospitalised patients. Drug Safety, 22, 321–333. https://doi.org/10.2165/00002018-200022040-00005
- Van Leeuwen, R. W. F., Brundel, D. H. S., Neef, C., van Gelder, T., Mathijssen, R. H. J., Burger, D. M., & Jansman, F. G. A. (2013). Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. British Journal of Cancer, 108, 1071–1078. https://doi.org/10.1038/bjc.2013.48
- Vantard, N., Ranchon, F., Schwiertz, V., Gourc, C., Gauthier, N., Guedat, M.-G., He, S., Kiouris, E., Alloux, C., You, B., Souquet, P.-J., Freyer, G., Salles, G., Trillet-Lenoir, V., & Rioufol, C. (2015). EPICC study: Evaluation of pharmaceutical intervention in cancer care. Journal of Clinical Pharmacy and Therapeutics, 40, 196–203. https://doi.org/10.1111/jcpt.12242
- Vo, H. T., Charpiat, B., Chanoine, S., Juste, M., Roubille, R., Rose, F.-X., Conort, O., Allenet, B., Bedouch, P., & Working Group “Valorization of Pharmacist Interventions” of the French Society of Clinical Pharmacy. (2021). CLEO: A multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions. European Journal of Hospital Pharmacy: Science and Practice, 28, 193–200. https://doi.org/10.1136/ejhpharm-2020-002642
- WHO. (2022). Anatomical therapeutic chemical (ATC) classification [text]. Retrieved from https://www.who.int/tools/atc-ddd-toolkit/atc-classification
- Yeoh, T. T., Si, P., & Chew, L. (2013). The impact of medication therapy management in older oncology patients. Supportive Care in Cancer, 21, 1287–1293. https://doi.org/10.1007/s00520-012-1661-y
- Yeoh, T. T., Tay, X. Y., Si, P., & Chew, L. (2015). Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. Journal of Geriatric Oncology, 6, 280–287. https://doi.org/10.1016/j.jgo.2015.05.001
- Zerbit, J., Chevret, S., Bernard, S., Kroemer, M., Ablard, C., Harel, S., Brice, P., Madelaine, I., & Thieblemont, C. (2020). Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: An observational cohort study. Annals of Hematology, 99, 1615–1625. https://doi.org/10.1007/s00277-020-04045-y
- Zerillo, J. A., Goldenberg, B. A., Kotecha, R. R., Tewari, A. K., Jacobson, J. O., & Krzyzanowska, M. K. (2017). Interventions to improve oral chemotherapy safety and quality: A systematic review. JAMA Oncology, 4, 105–117. https://doi.org/10.1001/jamaoncol.2017.0625
